Position in VTVT
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$1,882,500
New position
Shares Held
50,000
first reported quarter
Ownership
1.26%
of shares outstanding
% of Portfolio
0.40%
of 13F equity value
Holder Rank
#8
of 45 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Aisling Capital Management LP holds $451,349,309 across 13 Biotechnology names. VTVT ranks #11 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
4,589,611 | $341,834,227 | |
| 2 | GLUE |
Monte Rosa Therapeutics, Inc.
|
1,555,664 | $37,647,068 | |
| 3 | SNDX |
Syndax Pharmaceuticals Inc
|
1,316,806 | $28,785,379 | |
| 4 | BCAX |
Bicara Therapeutics Inc.
|
568,919 | $16,891,205 | |
| 5 | BBOT |
BridgeBio Oncology Therapeutics, Inc.
|
1,018,018 | $7,757,297 | |
| 6 | SRRK |
Scholar Rock Holding Corp
|
77,031 | $4,236,705 | |
| 7 | URGN |
UroGen Pharma Ltd.
|
108,000 | $3,974,400 | |
| 8 | BMEA |
Biomea Fusion, Inc.
|
2,048,757 | $3,011,672 |
All Filings in VTVT
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,882,500 | 50,000 | Shares | Sole | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||